262 results match your criteria: "Reactive Perforating Collagenosis"
Acquired reactive perforating collagenosis secondary to Cabozantinib: A case report and literature review.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, University of Calgary, Calgary, AB, Canada.
Acquired perforating dermatoses (APD) encompass a group of skin conditions distinguished by transepidermal elimination of dermal components. Acquired reactive perforating collagenosis (ARPC), a subtype of APD, has been reported most commonly in association with diabetes mellitus, chronic renal failure, and medications. In this report, we identify a novel case of ARPC secondary to Cabozantinib treatment.
View Article and Find Full Text PDFA case of acquired reactive perforating collagenosis after COVID-19 infection.
Postepy Dermatol Alergol
October 2024
Dermatology Hospital of Jiangxi Province, Jiangxi Provincial Clinical Research Center for Skin Diseases, Candidate Branch of National Clinical Research Center for Skin Diseases, Dermatology Institute of Jiangxi Province, The Affiliated Dermatology Hospital of Nanchang University, Nanchang, China.
A case of segmental acquired reactive perforating collagenosis: case report and literature review of the unique presentation.
An Bras Dermatol
November 2024
Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
[Reactive Perforating Collagenosis in Hemodialysis Patients].
G Ital Nefrol
October 2024
Presidio Ospedaliero Maria SS Addolorata Eboli, U.O.C. di Nefrologia e Dialisi.
Chronic Kidney Disease associated Pruritus (CKD-aP) in hemodialysis affects approximately 38% of our patients. It is not associated with any dermatological lesion other than the common scratching lesions, a consequence of the symptom itself. The causes associated with itching have been studied in various treatments.
View Article and Find Full Text PDFA Novel Case of Reactive Perforating Collagenosis (RPC) with Cutaneous Infiltration of EBV+ Angioimmunoblastic T-cell Lymphoma (AITL).
Clin Exp Dermatol
September 2024
Department of Dermatology, Dartmouth Health, Lebanon, NH, USA.
Reactive Perforating Collagenosis: Answer.
Am J Dermatopathol
October 2024
Department of Dermatology, Brigham and Women's Hospital, Boston, MA.
Anti-p200 Pemphigoid Mimicking Acquired Reactive Perforating Collagenosis.
Acta Derm Venereol
September 2024
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Familial Reactive Perforating Collagenosis with Adolescence-Onset: A Rare Case Report and Literature Review.
Clin Cosmet Investig Dermatol
August 2024
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
Article Synopsis
- - Familial Reactive Perforating Collagenosis (FRPC) is a rare, benign skin condition primarily seen in young children, with fewer than 50 documented cases, and its causes and treatments remain unclear.
- - A case study of a 20-year-old male from Indonesia showed multiple skin papules across his body for over 7 years, and similar symptoms were present in his family.
- - The patient was successfully treated with a topical corticosteroid, desoximetasone, leading to significant improvement in skin lesions, suggesting corticosteroids could be a viable treatment for FRPC.
Ultra-high Potency Topical Corticosteroids as a Potential Trigger for Reactive Perforating Collagenosis.
Acta Derm Venereol
August 2024
Private Practice dermatology, Bellinzona, Switzerland.
Effectiveness of baricitinib in acquired reactive perforating collagenosis: a case report.
Front Immunol
July 2024
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Article Synopsis
- Acquired reactive perforating collagenosis (ARPC) is a challenging skin condition that doesn’t respond well to typical immunosuppressive treatments and negatively impacts patients' quality of life.
- An 81-year-old woman with chronic itching and ulcerated lesions was diagnosed with ARPC after showing poor response to standard medications, leading to the initiation of baricitinib therapy.
- The treatment resulted in gradual symptom improvement without any adverse reactions, indicating that baricitinib could be an effective maintenance therapy for ARPC.
A case report on acquired reactive perforating collagenosis.
Medicine (Baltimore)
July 2024
Department of Dermatology, The Second People's Hospital of Hefei, Hefei, Anhui, China.
Article Synopsis
- - Acquired reactive perforating collagenosis (ARPC) is a rare skin condition that is often misdiagnosed, but using noninvasive skin microscopy can enhance diagnostic accuracy.
- - Comprehensive patient evaluations are essential due to ARPC's link with systemic diseases, and treatment mostly focuses on alleviating symptoms with medications like pregabalin and prednisone.
- - This case report highlights that clinical dermoscopy aids in diagnosing ARPC effectively and that pregabalin capsules significantly help reduce itching symptoms.
Acquired reactive perforating collagenosis triggered by trauma with eosinophilia: a case report and literature review.
Front Med (Lausanne)
June 2024
The Dermatology Department of Shanxi Provincial People's Hospital, Five Hospital of Shanxi Medical University, Taiyuan, China.
Article Synopsis
- Acquired reactive perforating collagenosis (ARPC) is a rare skin condition where abnormal collagen fibers penetrate the outer skin layer and is often linked to health issues like diabetes or kidney disease.
- A case study presented a 67-year-old man who developed ARPC after experiencing trauma, despite having no other underlying health changes.
- Diagnosis involved various tests that confirmed ARPC with eosinophilia, highlighting the need for healthcare providers to consider trauma as a potential trigger when diagnosing this rare condition.
Erratum: Recalcitrant Reactive Perforating Collagenosis Successfully Treated with Dupilumab: A Case Report [Corrigendum].
Clin Cosmet Investig Dermatol
July 2024
Article Synopsis
- The text discusses a correction made to an article referenced by its DOI number, indicating that there was an error in the originally published version.
- The correction aims to clarify information or rectify inaccuracies found in the article.
- Such corrections are important for maintaining the integrity of academic research and ensuring that readers have access to accurate data.
A Case of Noonan Syndrome and Kyrle's Disease: Coincidence or Causality?
Acta Dermatovenerol Croat
March 2024
Marco Brusasco, MD, University of Parma, Via Gramsci 14, Parma, Italy;
Article Synopsis
- A 39-year-old woman with Noonan Syndrome and a RAF1 mutation presented with itchy lesions on her limbs that developed two months prior, characterized by multiple dome-shaped papules.
- Blood tests showed no abnormalities, but a skin biopsy revealed features consistent with Kyrle's disease, a type of perforating dermatosis.
- The patient was treated with narrowband UVB phototherapy, resulting in complete resolution of symptoms despite leaving residual atrophic scars.
Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis.
Case Rep Dermatol Med
June 2024
Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Article Synopsis
- Acquired reactive perforating collagenosis is a rare skin disorder where abnormal connective tissue pushes through the skin, often linked to systemic diseases like diabetes and chronic kidney disease, or inflammatory skin conditions like atopic dermatitis.
- The case study focuses on a 35-year-old man who had this condition along with atopic dermatitis and did not respond to typical treatments but achieved complete relief after 12 weeks of dupilumab therapy.
- Dupilumab, which targets specific cytokines involved in skin inflammation and itching, proved effective in treating both atopic dermatitis and the associated reactive perforating collagenosis in this patient, suggesting it could be a viable treatment option for others with similar conditions.
Recalcitrant Reactive Perforating Collagenosis Successfully Treated with Dupilumab: A Case Report.
Clin Cosmet Investig Dermatol
June 2024
Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China.
Reactive perforating collagenosis (RPC) is the most common form of the perforating dermatoses, which include RPC, elastosis perforans serpiginosa (EPS), perforating folliculitis (PF), and Kyrle disease (KD). In RPC, altered collagen of the dermis is extruded through the epidermis, which can be misdiagnosed as other skin diseases, such as vasculitis or prurigo nodularis. RPC is associated with a number of conditions, including diabetes mellitus, hepatitis, and renal failure, and thus the management of the coexisting diseases is important.
View Article and Find Full Text PDFEditorial: Epithelial immune microenvironment and inflammatory skin diseases.
Front Immunol
June 2024
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
A potential new treatment with upadacitinib for acquired reactive perforating collagenosis.
JAAD Case Rep
June 2024
Department of Dermatology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Reactive perforating collagenosis: dermoscopic aspects and differential diagnosis.
BMJ Case Rep
April 2024
Dermatology Venereology and Leprosy, Shri B M Patil Medical College Hospital and Research Centre, BLDE (Deemed to be University), Vijayapur, Karnataka, India
Acquired reactive perforating collagenosis in a patient with diabetes.
Cleve Clin J Med
April 2024
Department of Dermatovenereology, Chengdu Second People's Hospital, Chengdu, Sichuan, China
A Case of Noonan Syndrome and Kyrle Disease: Casualty or Causality?
Acta Dermatovenerol Croat
December 2023
Marco Brusasco, MD, Dermatology Section Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, Italy;
Article Synopsis
- A 39-year-old woman with Noonan Syndrome and RAF1 mutation presented with itchy skin lesions on her limbs, which were diagnosed as Kyrle disease (KD) after a detailed examination.
- KD is characterized by dome-shaped papules with a central keratotic plug and is often linked to systemic conditions such as chronic renal failure and diabetes, although this patient did not have these issues.
- Treatment involved narrowband UVB phototherapy, leading to complete resolution of symptoms, which highlights the importance of managing underlying health conditions in skin diseases like KD.
A giant variant of acquired reactive perforating collagenosis successfully treated with nemolizumab.
J Eur Acad Dermatol Venereol
September 2024
Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Dermoscopy of Familial Reactive Perforating Collagenosis.
J Cutan Med Surg
March 2024
Department of Dermatology and Venereology, Safdarjung Hospital and Vardhman Mahavir Medical College, New Delhi, Delhi, India.
Kyrle disease: a case report and literature review.
Eur Rev Med Pharmacol Sci
November 2023
Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.
Article Synopsis
- Perforating dermatoses are various skin disorders where skin tissue is eliminated through the epidermis, and they typically affect adults with other health issues like renal failure or diabetes.
- Kyrle disease is one type of perforating dermatosis, and this case report discusses a patient with Kyrle disease who also has chronic kidney disease, highlighting the need for proper treatment.
- The study emphasizes the importance of addressing itching and managing underlying health problems to improve the quality of life for patients suffering from Kyrle disease.